Brought to you by 
BTG raises £106mm to fund recent acquisitions
29 May 2013
Executive Summary
BTG PLC (treatments for cancer and other serious diseases) raised £106mm ($160.7mm) through the private placement of 32.2mm ordinary shares at £3.30 each (a 5% discount) to undisclosed buyers. Proceeds will fund BTG’s concurrent acquisitions of Nordion Inc.’s Targeted Therapies business (targeted radioactive liver cancer treatment; deal value of $200mm), and EKOS Corp. (developed an ultrasonic clot dissolving device; total potential value $220mm including earn-outs).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BTG raises £106mm to fund recent acquisitions
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice